Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shigeki Ito

Showing results (121-130 of 142) with videos related to

Pageof 15
Sort By:
Cancer Science|September 25, 2020
Prognosis of patients with adult T-cell leukemia/lymphoma in Japan: A nationwide hospital-based studyYoshitaka Imaizumi, Masako Iwanaga, Kisato Nosaka, et al.
International Journal of Hematology|October 29, 2022
Validation of the iATL-PI prognostic index in therapeutic decision-making for patients with smoldering and chronic ATL: a multicenter studyYoshitaka Imaizumi, Masako Iwanaga, Kisato Nosaka, et al.
Experimental Hematology|February 16, 2023
The levels of serum soluble CD86 are correlated with the expression of CD86 variant 3 gene and are prognostic indicators in patients with myelomaRyosuke Kinoshita, Mariko Ishibashi, Hiroshi Handa, et al.
Annals of Hematology|February 18, 2021
Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA studyShinsuke Iida, Takayuki Ishikawa, Chang Ki Min, et al.
Journal of Clinical and Experimental Hematopathology : JCEH|June 2, 2011
Comparison of long-term clinical outcomes of CHOP chemotherapy between Japanese patients with nodal peripheral T-cell lymphomas and those with diffuse large B-cell lymphoma in the study group of the Tohoku Hematology ForumTomoaki Akagi, Naoto Takahashi, Kouhei Yamaguchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2016
Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia/Lymphoma: ATLL-002Takashi Ishida, Hiroshi Fujiwara, Kisato Nosaka, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 21, 2023
Isatuximab Plus Carfilzomib and Dexamethasone in East Asian Patients With Relapsed Multiple Myeloma: Updated IKEMA Subgroup AnalysisYawara Kawano, Kihyun Kim, Chang Ki Min, et al.
International Journal of Hematology|March 30, 2018
Bortezomib maintenance therapy in transplant-ineligible myeloma patients who plateaued after bortezomib-based induction therapy: a multicenter phase II clinical trialAtsushi Isoda, Kayoko Murayama, Shigeki Ito, et al.
European Journal of Haematology|February 24, 2015
A prospective analysis of clinical efficacy and safety in chronic myeloid leukemia-chronic phase patients with imatinib resistance or intolerance as evaluated using European LeukemiaNet 2013 criteriaKazunori Murai, Tomoaki Akagi, Kenji Shimosegawa, et al.
Leukemia Research|November 29, 2015
Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring CALR, JAK2V617F, JAK2Ex12del, and MPLW515L/K mutationsMasahiro Okabe, Hiroki Yamaguchi, Kensuke Usuki, et al.
Pageof 15

Showing results (121-130 of 142) with videos related to

Sort By:
Pageof 15
Cancer Science|September 25, 2020
Prognosis of patients with adult T-cell leukemia/lymphoma in Japan: A nationwide hospital-based studyYoshitaka Imaizumi, Masako Iwanaga, Kisato Nosaka, et al.
International Journal of Hematology|October 29, 2022
Validation of the iATL-PI prognostic index in therapeutic decision-making for patients with smoldering and chronic ATL: a multicenter studyYoshitaka Imaizumi, Masako Iwanaga, Kisato Nosaka, et al.
Experimental Hematology|February 16, 2023
The levels of serum soluble CD86 are correlated with the expression of CD86 variant 3 gene and are prognostic indicators in patients with myelomaRyosuke Kinoshita, Mariko Ishibashi, Hiroshi Handa, et al.
Annals of Hematology|February 18, 2021
Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA studyShinsuke Iida, Takayuki Ishikawa, Chang Ki Min, et al.
Journal of Clinical and Experimental Hematopathology : JCEH|June 2, 2011
Comparison of long-term clinical outcomes of CHOP chemotherapy between Japanese patients with nodal peripheral T-cell lymphomas and those with diffuse large B-cell lymphoma in the study group of the Tohoku Hematology ForumTomoaki Akagi, Naoto Takahashi, Kouhei Yamaguchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2016
Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia/Lymphoma: ATLL-002Takashi Ishida, Hiroshi Fujiwara, Kisato Nosaka, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 21, 2023
Isatuximab Plus Carfilzomib and Dexamethasone in East Asian Patients With Relapsed Multiple Myeloma: Updated IKEMA Subgroup AnalysisYawara Kawano, Kihyun Kim, Chang Ki Min, et al.
International Journal of Hematology|March 30, 2018
Bortezomib maintenance therapy in transplant-ineligible myeloma patients who plateaued after bortezomib-based induction therapy: a multicenter phase II clinical trialAtsushi Isoda, Kayoko Murayama, Shigeki Ito, et al.
European Journal of Haematology|February 24, 2015
A prospective analysis of clinical efficacy and safety in chronic myeloid leukemia-chronic phase patients with imatinib resistance or intolerance as evaluated using European LeukemiaNet 2013 criteriaKazunori Murai, Tomoaki Akagi, Kenji Shimosegawa, et al.
Leukemia Research|November 29, 2015
Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring CALR, JAK2V617F, JAK2Ex12del, and MPLW515L/K mutationsMasahiro Okabe, Hiroki Yamaguchi, Kensuke Usuki, et al.
Pageof 15